Source comparison
Comparison: Melanotan-1 Dosage Protocols for EPP Treatment
0.08mg/kg (Initial Titration) 5.6mg subcutaneous 20–30 days partial protection <5% 8–12% first dose Phase 2 safety data Subtherapeutic for most EPP patients. Use only as dose 1 in titration 0.16mg/kg (Standard Therapeutic) 11.2mg subcutaneous 45–60 days full p
This comparison does not assign a generated winner or score.
- 0.08mg/kg (Initial Titration)
- 5.6mg subcutaneous
- 20–30 days partial protection
- <5%
- 8–12% first dose
- Phase 2 safety data
- Subtherapeutic for most EPP patients. Use only as dose 1 in titration
- 0.16mg/kg (Standard Therapeutic)
- 11.2mg subcutaneous
- 45–60 days full protection
- 12–15% (mild, reversible)
- 15–18% first dose, <5% repeat
- Phase 3 RCT (NEJM 2015, JAAD 2020)
- Evidence-based standard. Balances efficacy and tolerability
- 0.20mg/kg (High-Dose)
- 14mg subcutaneous
- 50–65 days
- 22–28%
- 18–22%
- Exploratory Phase 2
- Marginal benefit vs 0.16mg/kg. Hyperpigmentation risk outweighs photoprotection gain
- 0.24mg/kg (Supraphysiologic)
- 16.8mg subcutaneous
- 55–70 days
- 31–38%
- 25–30%
- Single-arm observational
- Not recommended. Melanocyte response plateaus, adverse event rate unacceptable
- SCENESSE Implant (16mg controlled-release)
- 16mg implant (60-day release)
- 60 days consistent
- 10–12%
- 12–15%
- FDA-approved formulation
- Gold standard for EPP. Compounded injections at 0.16mg/kg mirror this kinetic profile